Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)
Ginkgo Bioworks acquires struggling synbio rival Zymergen in $300M all-stock deal
Ginkgo Bioworks is picking up a synthetic biology competitor in what it says is its largest M&A deal yet.
Ginkgo put out word early Monday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
